BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 25774481)

  • 1. Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.
    El-Mallawany NK; Cairo MS
    Clin Adv Hematol Oncol; 2015 Feb; 13(2):113-23. PubMed ID: 25774481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia.
    Miles RR; Arnold S; Cairo MS
    Br J Haematol; 2012 Mar; 156(6):730-43. PubMed ID: 22260323
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD20 positive childhood B-non Hodgkin lymphoma (B-NHL): morphology, immunophenotype and a novel treatment approach: a single center experience.
    Bilić E; Femenić R; Konja J; Simat M; Dubravcić K; Batinić D; Ries S; Rajić L
    Coll Antropol; 2010 Mar; 34(1):171-5. PubMed ID: 20432747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Humoral and cellular immunotherapy in ALL in children, adolescents, and young adults.
    Hochberg J; El-Mallawany NK; Cairo MS
    Clin Lymphoma Myeloma Leuk; 2014 Sep; 14 Suppl():S6-13. PubMed ID: 25486958
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy with the trifunctional anti-CD20 x anti-CD3 antibody FBTA05 (Lymphomun) in paediatric high-risk patients with recurrent CD20-positive B cell malignancies.
    Schuster FR; Stanglmaier M; Woessmann W; Winkler B; Siepermann M; Meisel R; Schlegel PG; Hess J; Lindhofer H; Borkhardt A; Buhmann R
    Br J Haematol; 2015 Apr; 169(1):90-102. PubMed ID: 25495919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Malignant non-Hodgkin's lymphoma of childhood and adolescence in Austria--therapy results between 1986 and 2000.
    Attarbaschi A; Mann G; Dworzak M; Trebo M; Urban C; Fink FM; Horcher E; Reiter A; Riehm H; Gadner H;
    Wien Klin Wochenschr; 2002 Dec; 114(23-24):978-86. PubMed ID: 12635465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Hodgkin and non-Hodgkin lymphoma of adolescents and young adults].
    Garciaz S; Coso D; Brice P; Bouabdallah R
    Bull Cancer; 2016 Dec; 103(12):1035-1049. PubMed ID: 27866679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathologic findings in high-grade B-cell lymphomas with typical Burkitt morphologic features but lacking the MYC translocation.
    Sevilla DW; Gong JZ; Goodman BK; Buckley PJ; Rosoff P; Gockerman JP; Lagoo AS
    Am J Clin Pathol; 2007 Dec; 128(6):981-91. PubMed ID: 18024324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches.
    Hernandez-Ilizaliturri FJ; Czuczman MS
    Oncology (Williston Park); 2009 May; 23(6):546-53. PubMed ID: 19544696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric Aggressive Mature B-Cell Lymphomas, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology.
    Davies K; Barth M; Armenian S; Audino AN; Barnette P; Cuglievan B; Ding H; Ford JB; Galardy PJ; Gardner R; Hanna R; Hayashi R; Kovach AE; Machnitz AJ; Maloney KW; Marks L; Page K; Reilly AF; Weinstein JL; Xavier AC; McMillian NR; Freedman-Cass DA
    J Natl Compr Canc Netw; 2020 Aug; 18(8):1105-1123. PubMed ID: 32755986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Diffuse large B-cell lymphomas and burkitt lymphoma.
    de Leval L; Hasserjian RP
    Hematol Oncol Clin North Am; 2009 Aug; 23(4):791-827. PubMed ID: 19577170
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of prior rituximab on outcomes of autologous stem-cell transplantation in patients with relapsed or refractory aggressive B-cell lymphoma: a multicentre retrospective Spanish group of lymphoma/autologous bone marrow transplant study.
    Redondo AM; Pomares H; Vidal MJ; Pascual MJ; Quereda B; Sancho JM; Polo M; López J; Conde E; Jarque I; Alonso N; Ramírez MJ; Fernández P; Sayas MJ; Requena MJ; Salar A; González JD; González-Barca E; Arranz R; Caballero D; Martín A
    Br J Haematol; 2014 Mar; 164(5):668-74. PubMed ID: 24274082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral blood lymphocyte/monocyte ratio predicts outcome in follicular lymphoma and in diffuse large B-cell lymphoma patients in the rituximab era.
    Belotti A; Doni E; Bolis S; Rossini F; Casaroli I; Pezzatti S; Pogliani EM; Pioltelli PE
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):208-13. PubMed ID: 25468321
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recent advances in the understanding and management of diffuse large B-cell lymphoma in children.
    Reiter A; Klapper W
    Br J Haematol; 2008 Jul; 142(3):329-47. PubMed ID: 18537979
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Comparison of the efficacy of CCCG-97 and BFM-90 protocols in the treatment for children with mature B-cell non-Hodgkin's lymphoma].
    Meng JH; Gao YJ; Lu FJ; Zhai XW; Wang HS; Li J
    Zhonghua Zhong Liu Za Zhi; 2012 Mar; 34(3):222-7. PubMed ID: 22780979
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab and its role as maintenance therapy in non-Hodgkin lymphoma.
    Collins-Burow B; Santos ES
    Expert Rev Anticancer Ther; 2007 Mar; 7(3):257-73. PubMed ID: 17338647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mature B-cell lymphoma and leukemia in children and adolescents-review of standard chemotherapy regimen and perspectives.
    Worch J; Rohde M; Burkhardt B
    Pediatr Hematol Oncol; 2013 Sep; 30(6):465-83. PubMed ID: 23570584
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 20. High-dose therapy and autologous stem cell transplantation in first relapse for diffuse large B cell lymphoma in the rituximab era: an analysis based on data from the European Blood and Marrow Transplantation Registry.
    Mounier N; Canals C; Gisselbrecht C; Cornelissen J; Foa R; Conde E; Maertens J; Attal M; Rambaldi A; Crawley C; Luan JJ; Brune M; Wittnebel S; Cook G; van Imhoff GW; Pfreundschuh M; Sureda A;
    Biol Blood Marrow Transplant; 2012 May; 18(5):788-93. PubMed ID: 22005647
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.